APLIF News and Press, Appili Therapeutics Inc From 02/02/21

Spartan Bioscience Board Chair Brings Broad Healthcare Experience to Appili’s Leadership Appili Therapeutics Inc. (TSX: APLI, OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious ...

Appili Therapeutics ([[APLIF]] -2.8%)  announced that its Phase 3 PRESECO (PREventing SEvere COvid-19) clinical trial is actively recruiting participants in 12 out of 20 planned sites in the United States.Appili said it will prioritize resources to accelerate recruitment a...

12 sites in the United States are actively recruiting for the double-blind placebo-controlled study in mild-to-moderate patients with COVID-19 The Company is prioritizing resources on the pivotal study and expects to provide interim data readout by late March 202 1 A...

Appili Therapeutics Inc. (TSX: APLI, OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, announced today that Appili’s CEO Dr. Armand Balboni will participate in HC Wainwright’s ...

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”), Appili Therapeutics (TSX: APLI, OTCQX: APLIF) and Global Response Aid FZCO (GRA) today announced that Dr. Reddy&#x...

Citing government sources, Kyodo News reports that Japanese health authorities have found it difficult to conclude the effectiveness of the anti-viral drug, Avigan, developed by Fujifilm Toyama Chemical Co., a unit of Fujifilm Holdings (FUJIF).The findings by the Pharmaceuticals and Medical D...

Dosing is underway in a Phase 3 clinical trial, PRESECO, evaluating Appili Therapeutics' (APLIF) Avigen tablets (favipiravir) for the treatment of COVID-19 patients with mild-to-moderate symptoms. The goal is to alleviate the symptoms and prevent disease progression.Enrollment target is ~826 ...

Randomized, double-blind, placebo-controlled study expected to enroll more than 800 outpatients with confirmed mild-to-moderate COVID-19 infections Appili’s broad COVID-19 clinical program focuses on the use of oral antivirals as an early intervention against the corona...

Company signs agreement with CRO and files Phase 3 clinical trial protocol with U.S. FDA in advance of anticipated study initiation in the U.S. Double-blind, randomized, placebo-controlled study will include approximately 1,156 participants in the U.S. and Canada; Appili expec...

Appili Therapeutics (APLIF): F1H GAAP EPS of -$0.09.Cash and short-term investments of $22.9M.Press Release For further details see: Appili Therapeutics reports F1H results